Does RA kill you? Let me count the ways….and what you can do about it
There were many presentations at EULAR 2018 in Amsterdam about the mortality of RA.
There were many presentations at EULAR 2018 in Amsterdam about the mortality of RA.
The annual EULAR meeting just came to an end today. Rooms are gradually emptying out. People look both content to have updated their knowledge and relieved that four very busy days have concluded. Time to summarize.
I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.
Day 3 highlights include Behcet’s responds to apremilast and that biologics do not differentially affect TKR/THR post-operative infection rates. Be sure to check out today's podcast as well.
This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.
You can also listen on iTunes, Soundcloud or Stitcher.
A big concern of most is the risk of infection with use of tumour necrosis factor inhibitor (TNFi) and biologic drugs. While studied in both trials and in post-marketing studies, it is unknown if infection risk is dose-dependent.
We're crazy busy at EULAR all week. Instead of this review, we recommend that you tune into our multiple podcasts from experts and faculty attending EULAR 2018 in Amsterdam. You can find these on iTunes, SoundCloud or Stitcher.
Each year I attend I hope that I’m going to come across something that changes my practice and this year, I think I may have struck gold at a session on Giant Cell arteritis at EULAR in Amsterdam.
This session was an update on the management of osteoporosis given by Professor Christian Roux from France.
As we gather more knowledge about psoriatic arthritis ( PsA) and psoriasis (PSO) over time, and achieve better outcomes with new therapies, more questions arise about quality of life, survival and comorbidities in PsA and PSO.
Highlights from Day 2 of the EULAR meeting in Amsterdam include high MBDA scores in ACPA negative RA predicts remission; characterization of difficult RA; and gender differences in psoriatic responses to TNF inhibitors.
This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.